Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases.
There is a controversy about the relation between anti-hepatitis B (anti-HBs) antibody level and obesity. We designed this study to compare the vaccine efficacy in obese/overweight and non-obese cases.



In this cross-sectional study, 242 obese/overweight and 85 non-obese individuals were participated. Cases were selected from a referral clinic for obesity and a referral hepatology clinic, both in Tehran, Iran.



Obese cases had lower percentage of liver diseases (66.9% vs. 100%, P<0.001) but higher hepatitis B vaccination history (74.9% vs. 51.2%, P<0.001). Median±inter-quartile range of anti-HBs titer in obese cases was significantly lower than controls (48.5±194.5 vs. 100±557.6, P=0.012).



The level of anti-HBs surface antigen antibody's titer in obese cases without liver disease is lower than control group. Therefore, a suitable strategy is needed to overcome this problem, which can be the use of longer needles for vaccination.
Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran.
Ali
A
Kabir
Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran.
Abdolreza
A
Pazouki
Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran.
Motahareh
M
Jafari
Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran.
Somayye
S
Mokhber
Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran.
Mohammad
M
Vaziri
Middle East Liver Disease Center, Tehran, Iran.
Seyed Moayed
SM
Alavian
Hepatitis B vaccines; Obesity; Liver diseases; Immunosuppressive agent